News

Gender matter! EUKON move on mission 5

Caserta, ITALY – August 8th, 2023   We are absolutely…

Read More >

EUKON FT1000 ranking 2022 on Financial Times

FT 1000: the sixth annual list of Europe’s fastest-growing companies…

Read More >

EUKON Leader della Crescita 2022

Leader della Crescita is  rank of first 450 companies, done…

Read More >

Next Generation PCI - Symposia at GISE 42, Milan 7th Oct 2021

EUKON and SMT present Next Generation PCI Symposia at GISE…

Read More >

Expanding your frontiers in Structural Interventions - Symposia at GISE 42, Milan 7th Oct 2021

EUKON SMT present Innovations in Structural Heart Intervention PFO and TAVI…

Read More >

FAVOR III China: QFR-Guided PCI Strategy vs. Angiography-Guided Strategy

FAVOR III China has bees published on Lancet and simultaneously…

Read More >

15 minutes with... - Interview to dr. Stefano Galli

Dr Stefano Galli Interventional Cardiologist at “Cardiologico Monzino” in Milan…

Read More >

It continues the interview series to experts on "The Vulnerable Patient"

In this interview Dr Simone Biscaglia, S. Anna University in…

Read More >

EUKON and M.A.C. Healthcare Cybersecurity

Caserta, ITALY – September 8th, 2021 —  EUKON’ experience in…

Read More >

Multicenter clinical evaluation of a piezoresistive-MEMSsensor rapid-exchange pressure microcatheter system for fractional flow reserve measurement-2021

  Multicenter-clinical-evaluation-of-a-piezoresistive-MEMSsensor-rapid-exchange-pressure-microcatheter-system-for-fractional-flow-reserve-measurement-2021.pdf This multicenter, prospective clinical study investigates whether the…

Read More >

New interview on theme of VULNERABLE PATIENT.

Today dr Luigi di Serafino of University Federico II in…

Read More >

15 minutes with... - Interview to prof. Paolo Calabrò

The VULNERABLE PATIENT WHO is the vulnerable patient ? HOW…

Read More >

SUPRAFLEX-TALENT trial 3yr follow-up has been presented at EuroPCR 2021

At EuroPCR 2021  TALENT 3yrs follow up has been presented.…

Read More >

“CONTEMPORARY ADOPTION OF INVASIVE CORONARY PHYSIOLOGY WITH MICROCATHETER-BASED TECHNOLOGY”

Physiology-guided PCI in MVD Chairman Prof. Emanuele Barbato and Dr…

Read More >

EUKON GO GREEN

Caserta, ITALY – April 9, 2021 With its mission to…

Read More >

IVUS + NIRS: The PROSPECT II Study Published on The Lancet

11 March 2021 The PROSPECT II Study has been published…

Read More >

TOBI IRAN 2021 BREAKING NEWS!

February 26th and March 12th   EUKON & Insight Lifetech…

Read More >

JIM 2021 BREAKING NEWS!

February 11th and 12th   EUKON & Insight Lifetech Co.,…

Read More >

‘True North’ Precise PCI Training Courses FFR Online Summit Forum Feb 5th, 2021

February 5th(Fri.) 9:00-11:10 am (C.E.T.) Insight Lifetech Co., Ltd We…

Read More >

APT Symposium CTO Feb 4th, 2021

CollecTiOn Sharing Expertise through West and East Chairperson: Prof. Jianping…

Read More >

QFR - Functional assessment of one or more coronary lesions?

It’s time of QFR the most innovative, accurate, easy and…

Read More >

TEST DAY SUPRAFLEX CRUZ

Ready for the future …ready for CRUZ the most deliverable…

Read More >

NEWS at GISE CTO 2020

Claudia Mugnoz interviews Prof. Varbella and Dr. Cerrato “Evolution and…

Read More >

True Physio Microcatheter for FFR in Italy soon!

After get approval from National Medical Products Admnistation and CE…

Read More >

Expert opinion on TALENT Study

Eminent cardiologists speak about SUPRAFLEX

Read More >

Suite MR

How can we use MEDIS Suite MR?

Read More >

TALENT 2yr at TCT 2019

Prof. Zaman present TALENT two years result at TCT 2019

Read More >

QFR

QFR for assessing Coronary Obstructions

Read More >

NIRS-IVUS for decision making in ACS

How can influence NIRS-IVUS of interventional cardiologists daily?

Read More >

IVUS + NIRS: The PROSPECT II Study

The PROSPECT II study was presented as Late-Breaking Clinical Trials…

Read More >

IVUS + NIRS: The PROSPECT ABSORB Study

For read click on The PROSPECT ABSORB Study (Jacc 2020)

Read More >

Are you curious about QFR?

Watch our new video about QFR 2.0. Don’t miss it…

Read More >